A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
To determine whether treatment with alpelisib plus fulvestrant prolongs progression-free
survival compared to fulvestrant and placebo in men and postmenopausal women with hormone
receptor positive (HR+), HER2-negative advanced breast cancer, who received prior treatment
with an Aromatase Inhibitor either as (neo)adjuvant or for advanced disease.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society